Intellect Neurosciences Inc. (fka ILNS)

[KaOsiris]

Could UCI grant be used for ILNS Tauc3 research?

UCI receives $11 million grant to continue ground-breaking Alzheimer's research

April 16, 2015

Updated 11:01 p.m.


[...]
UC Irvine announced Thursday that the institute has received a five-year, $11 million grant from the National Institute on Aging to renew its status as one of 27 Alzheimer’s Disease Research Centers in the country and the only one in Orange County.

The award will allow the center to continue its programs targeting clinical and basic research as well as community and caregiver education programs, LaFerla said.
[...]
The center also does pharmacological research, studying the effectiveness of medications for Alzheimer’s patients. Currently, Alzheimer’s patients have limited options with drugs, most of which only have a moderate impact, McAleer said.

“We’re hoping future research shows the way to medications to prevent or effectively treat this disease,” he said.
------------------------------

Of course, this is pure speculation as the article does not explicitly state that the grant will be used for TauC3 research.
However, LaFerla did TauC3 research for ILNS:

ILNS website: Internal pipeline:


In January 2014, we announced top line data showing proof of concept in a preclinical Alzheimer's model indicating the antibody’s potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau, indicating that the treatment with the peripherally administered antibody had an effect in the brain and is potentially disease modifying.

We have developed a detailed plan to corroborate these preliminary findings in additional models. This work will be outsourced to specialist contract research organizations and will involve collaboration with a leading AD investigator who has developed sophisticated models that are particularly well suited to test the TauC3 antibody.